Understanding how blood transfusions can lead to immune responses in patients.
Official title: Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 2
Funded at University of Virginia · NIH-11070285 · Data updated 2026-11-12
This study is looking into why some people develop antibodies after receiving blood transfusions while others don’t, focusing on how certain signals in the body might affect this response, which could help improve care for patients needing transfusions.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | September 10, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $438,679 |
| NIH project number | 5P01HL169552-02 |
| Project ID | NIH-11070285 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients who require chronic blood transfusions and may be at risk of developing alloantibodies.
✕Less likely to help
Patients who do not require blood transfusions or have no history of transfusion-related complications may not benefit from this research.
What this research studies
This research investigates why some patients develop antibodies against transfused red blood cells (RBCs) while others do not. It focuses on the role of purinergic signaling, a process involving ATP and its receptors, in influencing the immune response to transfusions. By using a mouse model, the study aims to uncover the molecular mechanisms that differentiate patients who produce multiple antibodies from those who do not, potentially leading to better management of transfusion-related complications.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing harmful immune responses in patients receiving blood transfusions.
How similar studies have gone: Previous research has shown that understanding immune responses to transfusions can lead to significant advancements in patient care, indicating that this approach has potential for success.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Luckey, Chance Marion John — University of Virginia
- Study coordinator: Luckey, Chance Marion John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.